- Home
- BANR vs CNTA Comparison
BANR vs CNTA Comparison
Compare BANR & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANR | CNTA |
|---|---|---|
| Founded | 1890 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BANR | CNTA |
|---|---|---|
| Price | $66.41 | $26.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $71.20 | $37.70 |
| AVG Volume (30 Days) | 175.5K | ★ 1.8M |
| Earning Date | 01-21-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | ★ 14.84 | N/A |
| EPS | ★ 5.49 | N/A |
| Revenue | ★ $640,027,000.00 | $15,000,000.00 |
| Revenue This Year | $0.69 | N/A |
| Revenue Next Year | $9.90 | N/A |
| P/E Ratio | $12.09 | ★ N/A |
| Revenue Growth | 7.86 | ★ 118.88 |
| 52 Week Low | $54.01 | $9.60 |
| 52 Week High | $74.06 | $30.58 |
Technical Indicators
Market Signals| Indicator | BANR | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 65.02 | 45.51 |
| Support Level | $64.18 | $28.43 |
| Resistance Level | $67.53 | $30.02 |
| Average True Range (ATR) | 1.35 | 1.34 |
| MACD | 0.39 | -0.40 |
| Stochastic Oscillator | 80.05 | 18.64 |
Price Performance
Historical ComparisonAbout BANR Banner Corporation
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.